Telix Pharmaceuticals (TLX) Receivables - Net (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Receivables - Net for 3 consecutive years, with $129.2 million as the latest value for Q4 2025.

  • Quarterly Receivables - Net rose 41.68% to $129.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $129.2 million through Dec 2025, up 41.68% year-over-year, with the annual reading at $129.2 million for FY2025, 48.63% up from the prior year.
  • Receivables - Net for Q4 2025 was $129.2 million at Telix Pharmaceuticals, up from $91.2 million in the prior quarter.
  • The five-year high for Receivables - Net was $129.2 million in Q4 2025, with the low at $42.2 million in Q4 2023.
  • Average Receivables - Net over 3 years is $87.5 million, with a median of $91.2 million recorded in 2024.
  • The sharpest move saw Receivables - Net soared 116.25% in 2024, then skyrocketed 41.68% in 2025.
  • Over 3 years, Receivables - Net stood at $42.2 million in 2023, then skyrocketed by 116.25% to $91.2 million in 2024, then surged by 41.68% to $129.2 million in 2025.
  • According to Business Quant data, Receivables - Net over the past three periods came in at $129.2 million, $91.2 million, and $42.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.